164 related articles for article (PubMed ID: 33118677)
1. Combined isobutylamido thiazolyl resorcinol and low-fluence Q-switched Nd: YAG laser for the treatment of facial hyperpigmentation: A randomized, split-face study.
Vachiramon V; Leerunyakul K; Kositkuljorn C; Chayavichitsilp P
J Cosmet Dermatol; 2021 Jun; 20(6):1724-1731. PubMed ID: 33118677
[TBL] [Abstract][Full Text] [Related]
2. Low-fluence Q-switched Nd: YAG 1064-nm laser and intense pulsed light for the treatment of melasma.
Vachiramon V; Sirithanabadeekul P; Sahawatwong S
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1339-46. PubMed ID: 25413592
[TBL] [Abstract][Full Text] [Related]
3. A randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma.
Fabi SG; Friedmann DP; Niwa Massaki AB; Goldman MP
Lasers Surg Med; 2014 Sep; 46(7):531-7. PubMed ID: 24895301
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of isobutylamido thiazolyl resorcinol for prevention of laser-induced post-inflammatory hyperpigmentation: A randomized, controlled trial.
Vachiramon V; Sakpuwadol N; Yongpisarn T; Anuntrangsee T; Palakornkitti P
J Cosmet Dermatol; 2024 Jul; 23(7):2450-2457. PubMed ID: 38497328
[TBL] [Abstract][Full Text] [Related]
5. Low-fluence Q-switched Nd:YAG 1064-nm laser versus Q-switched Nd:YAG 532-nm laser in the treatment of hyperpigmented lips: a prospective, randomized, controlled, evaluator-blinded trial.
Limpjaroenviriyakul N; Jurairattanaporn N; Kamanamool N; Rojhirunsakool S; Kanokrungsee S; Udompataikul M
Lasers Med Sci; 2020 Feb; 35(1):165-171. PubMed ID: 31177406
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the safety and efficacy of low fluence Q-switched 1064-nm and conventional Q-Switched 755-nm lasers in the treatment of café-au-lait macules: A prospective self-controlled trial.
Cen Q; Zhu J; Zhou L; Yu W; Wu X; Liu Y; Ma G; Luo L; Lin X
Lasers Surg Med; 2022 Oct; 54(8):1051-1059. PubMed ID: 36084202
[TBL] [Abstract][Full Text] [Related]
7. Isobutylamido thiazolyl resorcinol for prevention of UVB-induced hyperpigmentation.
Vachiramon V; Kositkuljorn C; Leerunyakul K; Chanprapaph K
J Cosmet Dermatol; 2021 Mar; 20(3):987-992. PubMed ID: 32757247
[TBL] [Abstract][Full Text] [Related]
8. Treatment of melasma in men with low-fluence Q-switched neodymium-doped yttrium-aluminum-garnet laser versus combined laser and glycolic acid peeling.
Vachiramon V; Sahawatwong S; Sirithanabadeekul P
Dermatol Surg; 2015 Apr; 41(4):457-65. PubMed ID: 25760554
[TBL] [Abstract][Full Text] [Related]
9. A split-face, investigator-blinded comparative study on the efficacy and safety of Q-switched Nd:YAG laser plus microneedling with vitamin C versus Q-switched Nd:YAG laser for the treatment of recalcitrant melasma.
Ustuner P; Balevi A; Ozdemir M
J Cosmet Laser Ther; 2017 Nov; 19(7):383-390. PubMed ID: 28657378
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of melasma treatment using a dual mode of low-fluence Q-switched and long-pulse Nd:YAG laser vs. low-fluence Q-switched Nd:YAG laser monotherapy.
Choi CP; Yim SM; Seo SH; Ahn HH; Kye YC; Choi JE
J Cosmet Laser Ther; 2015 Feb; 17(1):2-8. PubMed ID: 25151913
[TBL] [Abstract][Full Text] [Related]
11. Postinflammatory and rebound hyperpigmentation as a complication after treatment efficacy of telangiectatic melasma with 585 nanometers Q-switched Nd: YAG laser and 4% hydroquinone cream in skin phototypes III-V.
Lueangarun S; Namboonlue C; Tempark T
J Cosmet Dermatol; 2021 Jun; 20(6):1700-1708. PubMed ID: 33002283
[TBL] [Abstract][Full Text] [Related]
12. Long-term results in low-fluence 1064-nm Q-Switched Nd:YAG laser for melasma: Is it effective?
Gokalp H; Akkaya AD; Oram Y
J Cosmet Dermatol; 2016 Dec; 15(4):420-426. PubMed ID: 27349828
[TBL] [Abstract][Full Text] [Related]
13. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians.
Wattanakrai P; Mornchan R; Eimpunth S
Dermatol Surg; 2010; 36(1):76-87. PubMed ID: 20298254
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 0.15% isobutylamido thiazolyl resorcinol combined with hyaluronic acid vs 0.15% isobutylamido thiazolyl resorcinol or hyaluronic acid alone in melasma treatment: A randomized evaluator-blind trial.
Disphanurat W; Srisantithum B
J Cosmet Dermatol; 2021 Nov; 20(11):3563-3572. PubMed ID: 33638926
[TBL] [Abstract][Full Text] [Related]
15. A single-blinded, randomized, controlled trial comparing efficacy between low-fluence alexandrite 755-nm picosecond laser and low-fluence neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm picosecond laser for the treatment of ultraviolet B-induced hyperpigmentation.
Vachiramon V; Namasondhi A; Anuntrangsee T; Jurairattanaporn N
J Cosmet Dermatol; 2022 Mar; 21(3):1036-1044. PubMed ID: 34773725
[TBL] [Abstract][Full Text] [Related]
16. Low-power fractional CO₂ laser versus low-fluence Q-switch 1,064 nm Nd:YAG laser for treatment of melasma: a randomized, controlled, split-face study.
Jalaly NY; Valizadeh N; Barikbin B; Yousefi M
Am J Clin Dermatol; 2014 Aug; 15(4):357-63. PubMed ID: 24858737
[TBL] [Abstract][Full Text] [Related]
17. A split-face comparison of low-fluence Q-switched Nd: YAG laser plus 1550 nm fractional photothermolysis vs. Q-switched Nd: YAG monotherapy for facial melasma in Asian skin.
Kim HS; Kim EK; Jung KE; Park YM; Kim HO; Lee JY
J Cosmet Laser Ther; 2013 Jun; 15(3):143-9. PubMed ID: 23607714
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Riehl's Melanosis With Mid-Fluence Q-Switched Nd:YAG 1064-nm Laser.
Cho MY; Roh MR
Lasers Surg Med; 2020 Oct; 52(8):753-760. PubMed ID: 31951050
[TBL] [Abstract][Full Text] [Related]
19. Combining Low Power Fractional CO
Esmat S; Z Elramly A; Shahin D; Hilal RF
Lasers Surg Med; 2021 Dec; 53(10):1325-1340. PubMed ID: 34164829
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
Choi YJ; Nam JH; Kim JY; Min JH; Park KY; Ko EJ; Kim BJ; Kim WS
Lasers Surg Med; 2017 Dec; 49(10):899-907. PubMed ID: 28906574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
